We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
On the business, Keymed Biosciences Inc. and Lepu Biopharma jointly announced an exclusive global licensing agreement with AstraZeneca for CMG901. In terms of the listing, Kelun Pharmaceutical's subsidiary Kelun Biotech intends to go public in Hong Kong.
BPI-7711 is a third-generation EGFR-TKI, making Beta Pharma the fourth Chinese pharmaceutical enterprises that enter the Phase III clinical trial of the variety following ACEA, Hansoh, and Allist.